Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Medically stable patients undergoing more than one TPE procedure who have provided signed informed consent prior to participation.~2. A physician's prescription for TPE for various non-emergent conditions.~3. Test and Control TPE procedures that would be expected to be completed within approximately five weeks.~Exclusion Criteria:~1. Patients under 18 years old.~2. Patients on an ACE inhibitor medication should discontinue use of this medication in accordance with institutional practices.~3. Patients with altered mental status that would prohibit the giving and understanding of informed consent.~4. Patients who have experienced a serious adverse event associated with the first TPE clinical study procedure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMICUS Therapeutic plasma exchange, TPE (Type: EXPERIMENTAL): Patients are randomized to either TPE on AMICUS or Spectra.
- Spectra Therapeutic plasma exchange, TPE (Type: ACTIVE_COMPARATOR): Patients are randomized to either TPE on AMICUS or Spectra.

Based on this trial design, predict the completion outcome and termination type (if applicable).